What is NovoCure's D&A?

NovoCure (NVCR) reported D&A of $4.12M in Q1 2026.

How has NovoCure's D&A changed year-over-year?

NovoCure's D&A increased by 24.0% year-over-year, from $3.33M to $4.12M.

What is the long-term trend for NovoCure's D&A?

Over 4 years (2021 to 2025), NovoCure's D&A has grown at a 9.3% compound annual growth rate (CAGR), from $10.25M to $14.65M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

NovoCure NVCR D&A

D&A at other companies

Boston ScientificBSX

$351M+8.0%

MedtronicMDT

$716M-14.8%

Iovance Biotherapeutics, Inc.IOVA

$2.82M+9.8%

Nuvation BioNUVB

$536K+72.9%

Vir Biotechnology, Inc.VIR

$2.81M-2.0%

ArriVent BioPharma, Inc.AVBP

-$559K+26.1%

Other financials

Income statement

See full

Revenue$174.1M+12.3%

Gross profit$135.1M+16.0%

Operating income-$67.4M-78.1%

Net income-$71.1M-107%

EPS (diluted)-$0.62-100%

Balance sheet

See full

Cash & equivalents$87.5M-31.2%

Total debt$39.5M-2.1%

Total equity$330.7M-8.6%

Total assets$787.9M-36.9%

Cash flow

See full

Operating cash flow-$13.5M+62.1%

CapEx$5.2M-51.4%

Free cash flow-$18.7M+59.7%

Valuation

See full

Market cap$1.7B-36.7%

Enterprise value$1.66B-36.3%

P/S2.5×-1.8×

Profitability

See full

Gross margin75.2%-2.0pp

Operating margin-27.2%+0.4pp

Net margin-25.7%-0.7pp

FCF margin-7.1%-2.0pp

Returns & leverage

See full

Return on equity-50%+5.4pp

Debt / equity0.1×0.0×

Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NovoCure's D&A?: NovoCure (NVCR) reported D&A of $4.12M in Q1 2026.
How has NovoCure's D&A changed year-over-year?: NovoCure's D&A increased by 24.0% year-over-year, from $3.33M to $4.12M.
What is the long-term trend for NovoCure's D&A?: Over 4 years (2021 to 2025), NovoCure's D&A has grown at a 9.3% compound annual growth rate (CAGR), from $10.25M to $14.65M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.